Home › Head and Neck Squamous Cell Carcinoma › Virginia › Richmond
Head and Neck Squamous Cell Carcinoma clinical trials in Richmond, VA
12 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in and around Richmond (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RecruitingPhase 2/3
- Site #0129, Richmond
- Site #0138, Richmond
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecruitingPhase 2
- VCU Massey Comprehensive Cancer Center, Richmond
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Virginia Commonwealth University Massey Cancer Center, Richmond
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Enhancing Oral Cancer Awareness
RecruitingHealthy volunteers welcome
- Virginia Commonwealth University, Richmond
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
- VCU Massey Cancer Center, Richmond
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Bon Secours, Richmond
- Virginia Commonwealth University, Richmond
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RecruitingPhase 2
- Massey Cancer Center, Richmond
Head and Neck Squamous Cell Carcinoma trials in other cities
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- Nashville, TN39 studies
- New York City, NY39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Chicago, IL26 studies
- Philadelphia, PA26 studies
- Atlanta, GA24 studies
- San Antonio, TX22 studies
- Pittsburgh, PA22 studies
Other studies in Richmond
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer25 studies
- Prostate Cancer19 studies
- Heart Failure16 studies
- Lung Cancer14 studies
- Cardiovascular Disease13 studies
- Colorectal Cancer13 studies
- Steatotic Liver Disease12 studies
- Acute Myeloid Leukemia12 studies
- Metastatic Cancer12 studies
- Melanoma11 studies
- Obesity11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.